Trident Texofab Limited has announced a board meeting to discuss the financial results for the quarter and half-year.

The company continues to focus on its manufacturing operations, which drove 63.6% of revenue in FY25, with trading making up the remainder.

Revenue grew 27% year-on-year in Q4FY25 to ₹38.2 Cr and 23% for FY25 to ₹122 Cr.

EBITDA margins moderated to 4.48% in FY25 from 6.19% in FY24, impacted by rising costs despite the revenue growth.

Manufacturing remains the core strength, supported by recent capacity expansions and capital infusion to pursue growth opportunities.